Full-Time

Lead Production Operator

Piramal Pharma

Piramal Pharma

1,001-5,000 employees

CDMO and hospital generics, consumer health

No salary listed

Bethlehem, PA, USA

In Person

Category
Manufacturing & Production Operations (1)
Required Skills
SAP Products

Get referred to Piramal Pharma

See people who can refer or advise you

Requirements
  • A high school diploma is required.
  • A minimum of 3–5 years of related experience and/or training, or an equivalent combination of education and experience, is required.
  • Ability to read and interpret safety rules, operating and maintenance instructions, and procedure manuals.
  • Ability to write routine reports and correspondence clearly and professionally.
  • Mathematical ability to perform operations with whole numbers, fractions, and decimals and to compute rates, ratios, and percentages.
  • Ability to interpret bar graphs and scatter plots.
  • Ability to apply commonsense understanding to written, oral, or diagram-based instructions.
  • Ability to deal with problems involving multiple variables in standardized situations.
  • Ability to plan activities to ensure safe and reliable plant operations.
  • Good troubleshooting skills.
  • Mechanical aptitude with the ability to perform minor repairs and maintenance when needed.
  • Computer and automation aptitude with the ability to operate equipment using control systems.
  • Ability to multitask across automated and manual systems simultaneously.
  • Ability to prioritize workload and delegate tasks effectively.
  • Ability to wear a face-mask respirator and required personal protective equipment.
  • Ability to use hands to handle tools, equipment, and controls; communicate verbally; reach with hands and arms; and climb ladders as required.
  • Ability to stand, walk, sit, stoop, kneel, or crouch as required.
  • Ability to lift and/or move up to 50 pounds.
  • Close vision, distance vision, and the ability to adjust focus are required.
Responsibilities
  • Fill in for the Shift Supervisor during training or absence and lead the shift when the Shift Supervisor is off.
  • Follow operating procedures, rules, and instructions to work safely and remain familiar with relevant procedures.
  • Help drive 5S and SFTI initiatives in the Manufacturing department.
  • Plan, supervise, direct, and participate in daily production operations while anticipating potential production problems to minimize production loss and achieve production and quality objectives.
  • Assist operators in performing their duties to meet production goals.
  • Assist in troubleshooting automation and operational issues.
  • Enter and review SAP data related to production activities.
  • Submit work orders and coordinate work with the Maintenance team.
  • Report alarms and take appropriate corrective action.
  • Work with operators to verify proper operation of equipment.
  • Ensure manufacturing schedules and production goals are achieved.
  • Perform Production Operator and/or Control Room Operator duties when required, including running manual and automated process steps.
  • Produce accurate and complete manufacturing batch records using electronic and manual data.
  • Keep the manufacturing area and control systems audit-ready through current documentation and a clean, organized environment.
  • Cooperate with management and colleagues to maintain a safe and healthy working environment.
  • Create reports using electronic data from manufacturing systems.
  • Report personal injuries, near misses, and accidents to the supervisor and document them in WSO.
  • Perform work in accordance with Current Good Manufacturing Practices and 21 CFR 210 and 211 wherever applicable.
  • Read meters, gauges, or automatic recording devices at specified intervals to verify operating conditions.
  • Operate and control electric motors, pumps, and valves to regulate chemical flow.
  • Adjust manual controls or override automatic controls when directed to maintain operating ranges, switch to backup equipment, or shut down equipment when required.
  • Perform housekeeping duties, including sweeping, mopping, dusting, polishing, and waxing.
  • Assist Maintenance, Packaging, Warehouse, Engineering, and Quality Control departments when required.
  • Perform additional duties requested by the Shift Supervisor.

Piramal Pharma operates through three divisions: Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and the Consumer Products Division (CPD). PPS acts as a contract development and manufacturing organization (CDMO), offering development and manufacturing services across the drug lifecycle for clients in North America, Europe, and Asia. PCC specializes in complex hospital generics, especially inhaled anesthetics, serving the USA, Europe, and more than 100 countries. CPD markets consumer health brands in India, including Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri Activ, and aims to provide reliable development, manufacturing, and distribution capabilities to meet customer needs.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

India

Founded

2020

Get referred to Piramal Pharma

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 28, 2026 FY26 revenue held at ₹8,869 crore; Kenalog adds $30-40 million annualized sales.
  • Q4 FY26 cleared 30 inspections, including two US FDA visits without OAI findings.
  • FY26 capex reached $94 million, while Lexington and Riverview expansions advanced toward FY27.

What critics are saying

  • February 2026 Dahej closure over alleged hazardous dumping exposes Piramal to recurring plant shutdowns.
  • Q4 FY26 growth suffered inventory destocking, slower early-stage orders, and weak ex-US anesthesia demand.
  • Dahej shutdown plus repeat FDA findings can cripple PPS and PCC.

What makes Piramal Pharma unique

  • Yapan Bio subsidiary deepens PPS biologics and ADC capabilities across vaccines, gene therapies, and ADCelerate.
  • Piramal sells in 100-plus countries through 17 facilities and 6,000 hospitals.
  • Kenalog and inhaled-anesthetic expertise combine complex manufacturing with entrenched hospital-channel distribution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-6%

2 year growth

-1%
PR Newswire
Aug 18th, 2026
Piramal Pharma Limited completes acquisition of controlling stake in Yapan Bio Private Limited.

Piramal Pharma Limited completes acquisition of controlling stake in Yapan Bio Private Limited. Aug 18, 2026, 15:36 ET * Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing. * This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services. MUMBAI, India, Aug. 18, 2026 /PRNewswire/ - Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL. Finalized on August 18, 2026, the acquisition marks a major step forward in PPL's long-range plan to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary's advanced large molecule capabilities into its integrated service offering, enabling the Company to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate(TM)- PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate(TM) and reinforces PPL's ability to deliver life-saving ADCs to market with speed and consistency. "This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action," said Peter DeYoung, CEO, Piramal Global Pharma. "By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need." About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. SOURCE Piramal Pharma Solutions

Business Upturn
Aug 18th, 2026
Piramal Pharma acquires 40.67% stake in Yapan Bio for $9M, making it a subsidiary

Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio for ₹76 crore, increasing its shareholding from 33.33% to 74%. The Mumbai-based pharmaceutical company purchased 146,400 equity shares, converting Yapan Bio from an associate company to a subsidiary. Yapan Bio, founded in 2019, is a Contract Development and Manufacturing Organisation specialising in vaccines and biologics. The company reported revenues of ₹26.91 crore, ₹54.40 crore, and ₹26.34 crore for fiscal years 2024, 2025, and 2026 respectively. The acquisition strengthens Piramal Pharma's biologics capabilities and expands its integrated service offerings. The company announced its intention to exercise this call option in August 2026, completing the transaction as disclosed in a regulatory filing to the National Stock Exchange.

Multibagg AI
Aug 10th, 2026
Piramal Pharma invests $14.6M in biologics CDMO Yapan Bio, raises stake to 33.33%

Piramal Pharma Ltd invested INR 101.77 crore in Hyderabad-based Yapan Bio Pvt Ltd in December 2021, acquiring a 27.78% equity stake. The investment aimed to strengthen Piramal Pharma Solutions' CDMO capabilities in biologics and vaccines, particularly for large molecule development and manufacturing for human clinical trials. In April 2022, Piramal increased its stake by 5.55% for Rs 20.35 crore, bringing total ownership to 33.33% by March 2023. The company's FY2023 filings showed Yapan's share of loss at Rs 0.20 crore. In October 2022, Yapan expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, as part of a $1 million expansion plan. The facility supports end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. Yapan's services are marketed through Piramal Pharma Solutions.

Yahoo Finance
Apr 29th, 2026
India's Piramal Pharma targets earnings growth with complex cancer drug demand

Piramal Pharma expects to accelerate earnings growth over the next two to three years, driven by rising demand for complex drugs including targeted cancer therapies, chairperson Nandini Piramal said. The Indian drugmaker, which derives 55% of revenue from contract manufacturing, aims for early-to-mid-teens revenue growth after reporting a 3% drop in fiscal 2026. The company is prioritising higher-value segments, particularly antibody-drug conjugates for cancer treatment, as global biotech funding into Indian contract manufacturers rebounds. Biotech funding in the second half of 2024 was 80% higher year-on-year, translating into increased order inflows. Piramal is avoiding generic weight-loss drug ingredients due to intense competition and falling prices. The company's contract manufacturing revenue fell 10% last year, causing margins to shrink from 17% to 13%.

PR Newswire
Apr 28th, 2026
Piramal Pharma reports $21M impairment amid inventory destocking but sees FY27 recovery

Piramal Pharma Limited announced results for Q4 and full-year FY26, reporting revenue growth impacted by inventory destocking, slower early-stage order inflows and softer inhalation anesthesia traction in ex-US markets. The company recognised an impairment loss of ₹176 crore on intangible assets under development. The pharmaceutical company invested $94 million in capex during FY26, with Lexington and Riverview expansions progressing. Net debt remained flat compared to FY25. Key developments included completing the Kenalog acquisition for $35 million upfront consideration plus up to $65 million contingent payment. The Consumer Healthcare division's Power Brands grew 24% year-on-year, whilst e-commerce sales surged 48%, contributing 27% to segment revenue. Chairperson Nandini Piramal stated all three business segments are positioned to deliver growth in FY27.